HAT1 and melanoma: We also confirmed that ~63% of progressed samples, from BRAF-mutant melanoma patients who experienced disease progression following BRAFi or BRAFi + MEKi therapy, showed significantly reduced HAT1 expression levels compared with matched pre-treatment samples.